Casey M. Cosgrove, MD, gynecologic oncologist, The Ohio State University Comprehensive Cancer Center–James, and assistant professor, Department of Gynecologic Oncology, The Ohio State University College of Medicine, discusses retreatment with PARP inhibitors in recurrent ovarian cancer.
Stephen Liu, MD, discusses the CheckMate-032 trial in small cell lung cancer.
Manuel Hidalgo Medina, MD, PhD, discusses microsatellite instability and germline testing patients with pancreatic cancer.
Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.
Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.
Massimo Cristofanilli, MD, discusses the need for biosimilars in oncology.
Mary J. Fidler, MD, discusses the utility of dacomitinib (Vizimpro) in patients with EGFR-mutant non–small cell lung cancer.
John Hays, MD, PhD, discusses investigational combinations of PARP inhibitors and immunotherapy in ovarian cancer.
Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.
Alexey V. Danilov, MD, PhD, discusses the utility of rituximab biosimilars in chronic lymphocytic leukemia.
Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.
Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.
John M. Pagel, MD, PhD, discusses the use of biosimilars in oncology and the importance of cost consciousness.
Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.
Ashish Saxena, MD, PhD, discusses the treatment landscape of ALK-positive non–small cell lung cancer.
Keith R. Unger, MD, discusses utilizing a multidisciplinary team to treat patients with gastroesophageal cancer.
Pavlos Msaouel, MD, PhD, discusses the rationale for a phase II study evaluating sitravatinib in combination with nivolumab in patients with metastatic or advanced urothelial cancer.
Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.
Jeffrey M. Fowler, MD, discusses the various types of surgical procedures in ovarian cancer.
Alexander Drilon, MD, discusses what factors he considers when selecting treatment for patients with ALK fusion-positive non–small cell lung cancer.
Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).
John Hays, MD, PhD, discusses the potential for PARP inhibitor combinations in patients with ovarian cancer.
Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.
Kaushal Parikh, MD, MBBS, discusses the KRAS inhibitors AMG 510 and MRTX849 in lung cancer.
I. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.
Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.
Mitchell R. Smith, MD, PhD, discusses the rationale behind the trial looking at the fixed duration of the ibrutinib and venetoclax combination in chronic lymphocytic leukemia.
Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.
Ulka Vaishampayan, MD, discusses the utility of immunotherapy in metastatic renal cell carcinoma.
